Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: kinase inhibitors - Exelixis

Drug Profile

Research programme: kinase inhibitors - Exelixis

Alternative Names: EXEL 0862; EXEL 2280; EXEL 2819; EXEL 2942; EXEL 6309; EXEL 7647; EXEL-8232; mTORC1/mTORC2 inhibitor (XL388); XL 388

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Exelixis
  • Class Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Aurora kinase A inhibitors; Insulin-like growth factor I inhibitors; Janus kinase-2 inhibitors; Mitogen-activated protein kinase kinase inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Phosphoric monoester hydrolase inhibitors; Phosphotransferase inhibitors; Proto oncogene protein c-akt inhibitors; Proto oncogene protein c-kit inhibitors; Raf kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer; Myeloproliferative disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Myeloproliferative disorders in USA (PO)
  • 19 Nov 2009 Pharmacodynamics data from preclinical trials in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top